Kurs
+5,11%
Kurs
+5,11%
Open
55,80
High
60,00
Low
55,80
Close
57,60
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
Tid* | ||
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-05-06 | N/A | Årsstämma |
2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-04-30 | - | Kvartalsrapport 2024-Q1 |
2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2024-04-29 | - | Årsstämma |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2023-05-04 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2022-05-18 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-08-25 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2021-05-04 | - | Årsstämma |
2021-04-16 | - | Kvartalsrapport 2021-Q1 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-10-29 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2020-05-14 | - | Årsstämma |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-21 | - | Extra Bolagsstämma 2019 |
2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-07-13 | - | Extra Bolagsstämma 2018 |
2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-06-06 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-06-18 07:30:00
Gentian Diagnostics ASA has the pleasure of inviting to a virtual presentation
on Thursday 24 June 2021 at 10:00-11.00 am CEST in relation with the company's
updated investor presentation and new long-term ambition (see separate stock
exchange release earlier today).
Gentian's CEO Hilja Ibert, CSO Erling Sundrehagen and CFO Njaal Kind will
present the company followed by a Q&A session.
Join the online presentation via the following link:
https: https://streams.eventcdn.net/gentian/company-presentation/
Questions can be submitted during the online webcast.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.